'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Torrent Pharmaceuticals has increased 8.61% to Rs 2889 crore. Operating profit margin has jumped from 31.02% to 32.50%, leading to 13.82% rise in operating profit to Rs 939.00 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 15.89% to 11.50%. Purchase of finished goods cost rose from 10.72% to 13.04%. Employee cost increased from 18.46% to 18.53%. Other expenses rose from 24.66% to 24.88%.
PBIDT rose 8.46% to Rs 923 crore. Provision for interest fell 29.67% to Rs 64 crore. Loan funds declined from Rs 4,487.00 crore as of 30 September 2023 to Rs 3,128.00 crore as of 30 September 2024. Sundry debtors were higher at Rs 1,783.00 crore as of 30 September 2024 compared to Rs 1...
Pleaselogin & subscribe to view the full report.
More Reports
-
Revenue up 11% YoY to Rs 33562.9 crore in Q2FY2025
-
(18-Nov-2024)
Bharat Forge
-
-
|
|